# Qualitatively distinct modes of Sputnik V vaccine-neutralization escape by SARS-CoV-2 Spike variants.

Satoshi Ikegame<sup>1,#</sup>, Mohammed N. A. Siddiquey<sup>2,#</sup>, Chuan-Tien Hung<sup>1</sup>, Griffin Haas<sup>1</sup>, Luca Brambilla<sup>1</sup>, Kasopefoluwa Y. Oguntuyo<sup>1</sup>, Shreyas Kowdle<sup>1</sup>, Ariel Esteban Vilardo<sup>3</sup>, Alexis Edelstein<sup>3</sup>, Claudia Perandones<sup>3, †</sup>, Jeremy P. Kamil<sup>2, †</sup>, and Benhur Lee<sup>1, †,\*</sup>

# Affiliations.

1. Department of Microbiology at the Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

2. Department of Microbiology and Immunology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.

3. National Administration of Laboratories and Health Institutes of Argentina (ANLIS) Dr. Carlos G. Malbrán, Buenos Aires, Argentina

# These authors contributed equally to the study.

<sup>†</sup> Senior authors

<sup>\*</sup> Correspondence to: Benhur Lee, benhur.lee@mssm.edu

**Competing interests:** B.L. and K.Y.O. are named inventors on a patent filed by the Icahn School of Medicine for some of the materials used in this work. J.P.K. is a consultant for BioNTech (advisory panel on coronavirus variants).

### ABSTRACT.

The novel pandemic betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected at least 120 million people since its identification as the cause of a December 2019 viral pneumonia outbreak in Wuhan, China. Despite the unprecedented pace of vaccine development, with six vaccines already in use worldwide, the emergence of SARS-CoV-2 'variants of concern' (VOC) across diverse geographic locales suggests herd immunity may fail to eliminate the virus. All three officially designated VOC carry Spike (S) polymorphisms thought to enable escape from neutralizing antibodies elicited during initial waves of the pandemic. Here, we characterize the biological consequences of the ensemble of S mutations present in VOC lineages B.1.1.7 (501Y.V1) and B.1.351 (501Y.V2). Using a replication-competent EGFP-reporter vesicular stomatitis virus (VSV) system, rcVSV-CoV2-S, which encodes S from SARS coronavirus 2 in place of VSV-G, and coupled with a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient S-mediated infection, we determined that 8 out of 12 (67%) serum samples from a cohort of recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed dose response curve slopes indicative of failure to neutralize rcVSV-CoV2-S: B.1.351. The same set of sera efficiently neutralized S from B.1.1.7 and showed only moderately reduced activity against S carrying the E484K substitution alone. Taken together, our data suggest that control of emergent SARS-CoV-2 variants may benefit from updated vaccines.

#### INTRODUCTION.

The novel pandemic betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged as the etiologic agent of a viral pneumonia first detected in late 2019 (Huang *et al.*, 2020), which has since been designated Coronavirus Disease 2019 (COVID-19). To date, there have been over 120 million confirmed COVID-19 cases worldwide, leading to at least 2.65 million deaths (*COVID-19 Map - Johns Hopkins Coronavirus Resource Center*, no date). Although SARS-CoV-2 is newly emergent, two other closely related viruses within the sarbecovirus subgenus, MERS and SARS, also cause life-threatening respiratory infections (Boni *et al.*, 2020).

Due to the immense scale of this public health emergency, vaccines for prevention of COVID-19 have been developed at an unprecedented pace, and six are already authorized for human use in various countries around the world (Folegatti *et al.*, 2020; Polack *et al.*, 2020; Zhang *et al.*, 2020; Baden *et al.*, 2021; Logunov *et al.*, 2021; Sadoff *et al.*, 2021). The vast majority of vaccines are focused on the SARS-CoV-2 spike protein (S), due to its critical roles in cell entry. Indeed, the presence of serum neutralizing antibodies directed at S correlate strongly with protection against COVID-19 (Addetia *et al.*, 2020; Khoury *et al.*, 2021). Despite that these six vaccines appear to be efficacious, the recent emergence of novel SARS-CoV-2 variants has reignited concerns that the pandemic may not be so easily brought under control.

In December 2020, the United Kingdom reported the sudden emergence of a novel SARS-CoV-2 lineage, termed B.1.1.7 (501Y.V1, VOC 202012/01), which was designated as the first SARS-CoV-2 variant of concern (VOC). The lineage had rapidly increased in prevalence since first being detected in November 2020 (Andrew Rambaut, Nick Loman, Oliver Pybus, Wendy Barclay, Jeff Barrett, Alesandro Carabelli, Tom Connor, Tom Peacock, David L Robertson, Erik Volz, COVID-19 Genomics Consortium UK (CoG-UK), 2020). Its genome showed an unusually high number of non-synonymous substitutions and deletions, including eight in the S gene, suggesting a substantial degree of host adaptation that may have occurred during prolonged infection of an immunocompromised person, as has been previously observed (Choi *et al.*, 2020). The B.1.1.7 lineage has now been shown to exhibit enhanced transmissibility (Davies, Abbott, *et al.*, 2021) as well as an increased case fatality rate (Davies, Jarvis, *et al.*, 2021; Grint *et al.*, 2021).

Soon afterwards, two additional SARS-CoV-2 VOC, B.1.351 and P.1, were reported from S. Africa and Brazil, respectively, which each showed substantial escape from neutralizing antibodies elicited by first wave pandemic viruses, leading to documented cases of re-infection (Tegally *et al.*, 2020; Dejnirattisai *et al.*, 2021; Naveca *et al.*, 2021). The S genes of B.1.351 and P.1 viruses each carry a number of

mutations, but include three in the receptor binding domain (RBD) that are particularly notable, the S: N501Y substitution, found in B.1.1.7, alongside polymorphisms at positions 417 and 484, K417N/T and E484K. S: E484K had already been identified in multiple independent laboratories to confer escape from convalescent sera and monoclonal antibodies (Weisblum *et al.*, 2020; Greaney, Loes, *et al.*, 2021; Z. Liu *et al.*, 2021). As expected, the P.1 and B.1.351 variants escape or resist neutralization by first wave convalescent sera, as well as antibodies elicited by COVID-19 vaccines (Garcia-Beltran *et al.*, 2021; Wang *et al.*, 2021; Wibmer *et al.*, 2021; Y. Liu *et al.*, 2021; Zhou *et al.*, 2021).

Although the P.1 and B.1.351 lineages are dominant in Brazil and S. Africa, unlike B.1.1.7 they have not increased greatly in number in the United States since originally being detected here. In contrast, the E484K polymorphism is recurrently emergent, and is found in a number of other lineages that are increasing in the U.S. and other countries. For example, a B.1.526 sub-lineage carrying E484K in recent weeks has expanded more rapidly than B.1.1.7 (Annavajhala *et al.*, 2021; West *et al.*, 2021), which may be indicative of the ability of S: E484K variants to penetrate herd immunity. The P.2 lineage, originally detected in Rio de Janeiro, carries only the E484K mutation in the RBD and has spread to other parts of South America, including Argentina (Voloch *et al.*, 2021).

The six COVID-19 vaccines currently in use around the world employ different strategies, and do not all incorporate the two proline substitutions that "lock" S into the pre-fusion conformer. Vaccines that do not utilize pre-fusion "locked" S are expected to produce lower levels of neutralizing antibodies, and hence may be less efficacious against infection, even if they do protect against severe COVID-19. Indeed, a two-dose regimen of the AstraZeneca ChAdOx1 based vaccine, which does not use a "locked" S, did not protect against mild-to-moderate COVID-19 in S. Africa, where 93% of COVID-19 cases in trial participants were caused by the B.1.351 variant (Madhi et al., 2021). Like the AstraZeneca ChAdOx1 vaccine, the Sputnik V vaccine (Gam-COVID-Vac) is based on adenovirus vectored expression of a native S sequence, rather than a pre-fusion "locked" S (Logunov et al., 2020). Although the Sputnik V vaccine has a reported vaccine efficacy of 91.6% in the interim analysis of Phase 3 trials held in Russia between Sept 7 and Nov 24, 2020, none of the VOC mentioned above nor independent lineages containing the E484K mutation were prevalent in Russia during this time period. Since the Sputnik vaccine is now widely in use not only in Russia, but also in countries like Argentina, Chile, and Hungary, where some of the VOC and emerging lineages bearing the E484K mutation are more widespread, it is critical to assess the neutralizing activity of Sputnik vaccine elicited antibody responses against these cognate VOC and mutant spikes.

This study characterizes the neutralization activity of sera from a dozen Sputnik V vaccine recipients in Argentina. Our work was spurred by Argentina's nascent genomic surveillance efforts, which detected multiple independent lineages with S: E484K (B.1.1.318 and P.2) and/or S: N501Y substitutions (B.1.1.7 and P.1) in common, just as Argentina had started rolling out its vaccination campaign, which commenced on Dec 29, 2020. Here, we generated isogenic replication-competent vesicular stomatitis virus bearing the prevailing wild-type (WT=D614G) SARS-CoV-2 S (rcVSV-CoV2-S), or the B.1.1.7, B.1.351 or E484K mutant S and used them in a robust virus neutralization assay. Our results show that Sputnik V vaccine sera effectively neutralized S: WT and S: B.1.1.7. viruses, albeit with highly variable titers. The same sera, however, exhibited moderate and markedly reduced neutralization titers, respectively, against S: E484K and S: B.1.351. Analyses of dose response curves indicate that S: B.1.351 exhibits resistance to neutralizing sera in a manner that is qualitatively different from the E484K mutant. Taken together, our data argue that surveillance of the neutralizing activity elicited by vaccine sera will be necessary on an ongoing basis. Viral neutralization assays can indicate which SARS-CoV-2 variants are likely capable of transmission in the face of vaccine elicited immunity, and whether updated vaccines will be needed to control their emergence and spread.

#### **RESULTS.**

# Robust reverse genetics for generating replication competent VSV expressing SARS-CoV-2 Spike proteins.

Several groups have now generated replication-competent VSV expressing SARS-CoV-2 spike in place of VSV-G (rcVSV-CoV2-S)(Dieterle *et al.*, 2020; Li *et al.*, 2020)(Case, Rothlauf, Chen, Liu, *et al.*, 2020)(Baum *et al.*, 2020; Weisblum *et al.*, 2020)(Yahalom-Ronen *et al.*, 2020)(Baum *et al.*, 2020). These rcVSV-CoV2-S can be used in BSL-2 compatible virus neutralization assays (VNAs), which correlate very well with VNAs using live SARS-CoV-2 (Spearman's r > 0.9 across multiple studies). rcVSV-CoV2-S has been assessed as a candidate vaccine (Yahalom-Ronen *et al.*, 2020)(Case, Rothlauf, Chen, Kafai, *et al.*, 2020) and used in forward genetics experiments to generate antibody escape mutants or perform comprehensive epitope mapping studies (Greaney, Starr, *et al.*, 2021)(Weisblum *et al.*, 2020)(Baum *et al.*, 2020). Indeed, the now concerning E484K mutation, present in many variants of concern (VOC), was identified as an antibody escape mutation using rcVSV-CoV-2-S (Weisblum *et al.*, 2020)(Baum *et al.*, 2020).

However, many groups passage their rcVSV-CoV-2-S extensively in Vero cells after the initial rescue, either to generate higher titer stocks and/or to remove confounding components such as the vaccinia virus expressing T7-polymerase and/or transfected VSV-G, both of which were deemed necessary for efficient rescue (Baum *et al.*, 2020). Serial passage of rcVSV-CoV-2-S in Vero cells invariably leads to mutations in the S1/S2 furin cleavage site, as well as truncations in the cytoplasmic tail of the S protein (Yahalom-Ronen *et al.*, 2020). The latter promotes S incorporation into VSV without compromising the conformational integrity of the ectodomain, whereas the former is problematic when assessing the neutralization sensitivity and structure-function phenotype of Spike VOC with multiple mutations that likely have complex epistatic interactions.

To generate rcVSV-CoV2-S containing different variants or mutants on demand, without the need for extensive passaging, we developed a robust reverse genetics system and VNA which leverages the cell lines we previously developed for a standardized SARS-CoV-2 VNA that can be used for cross-cohort comparisons (Oguntuyo *et al.*, 2021). Fig. 1A provides schematic details for the generation of our rcVSV-CoV-S GFP reporter viruses. Salient improvements include the addition of a hammerhead ribozyme immediately upstream of the 3' leader sequence which cleaves *in cis* to give the exact 3' termini, the use of a CMV-driven codon-optimized T7-polymerase which alleviates the use of vaccinia-driven T7-polymerase, and a highly transfectable HEK-293T clone (F8-2) selected for optimal expression of hACE2 and

TMPRSS2 (Oguntuyo *et al.*, 2021) (Fig. 1B). A 6-plasmid transfection into F8-2 cells (Fig. 1A) results in GFP+ cells 2-3 days post-transfection (dpt). Some of these turn into foci of syncytia by 4 dpt indicating virus-replication and cell-to-cell spread. Transfer of F8-2 cell supernatant at this time point into interferon-defective Vero-TMPRSS cells allows for rapid expansion of low passage viral stocks that maintain only the engineered Spike mutations. Clarified but unconcentrated viral supernatants from Vero-TMPRSS2 cells were aliquoted, sequenced verified, then titered on F8-2 cells to determine the linear range of response (Fig. 1C).

Next, we generated isogenic rcVSV-CoV2-S expressing the B.1.1.7, B.1.351 (Fig. 2A), or E484K S to evaluate the neutralizing activity of Sputnik V vaccine sera from Argentina. The relevant Spike substitutions that make up these variants are indicated in Fig. 2A. The characteristics of the vaccine recipient cohort (n=12) receiving the two-dose regimen of the Sputnik vaccine are given in Table 1. At 1 month post completion of the two-dose regimen, the Sputnik V vaccine generated respectable virus neutralizing titers (VNT) against rcVSV-CoV2-S bearing the WT (D614G) and B.1.1.7 spike proteins (Fig. 2B). The geometric mean titer (GMT) and 95% CI for WT (GMT 49.4, 23.4 - 105) in our cohort of vaccine recipients was remarkably similar to that reported in the phase III Sputnik vaccine trial (GMT 44.5, 31.8 - 62.2)(Logunov et al., 2021). However, 9 of the 12 sera samples (75%) failed to achieve the 50% inhibitory threshold against the B.1.351 spike at the highest serum concentration used (1:20 dilution) whereas 6 of the 12 sera were able to do so against the E484K mutant spike (Fig. S1). Nonetheless, using the IC50 values that can be reasonably extrapolated, VNT against B.1.351 and E484K was reduced by a median 6.8- and 2.8-fold, respectively (Fig. 2C) compared to WT.

Further inspection of the dose-response curves revealed that the Sputnik vaccine recipients generate qualitatively different neutralizing antibody responses against SARS-CoV-2 (Fig.3A-D and Fig. S2) that could be classified into 4 different groups. Group (A) exemplified by SP009 showed reasonable VNT against wild-type (WT) and B.1.1.7 (VNT = 76 and 111, respectively). However, the Hill Slope of the neutralization curve for B.1.351 was extremely shallow (<1.0). This class of sera may achieve an IC<sub>50</sub> but will not attain an IC<sub>90</sub> even when extrapolated to the highest achievable serum concentration (1/serum dilution = 1). In contrast, although the reciprocal IC50 for E484K is moderately decreased (VNT = 23), it is clear that E484K will still be neutralized at higher serum concentrations due to a significantly steeper Hill Slope (>1.0). Group (B) sera exhibit effective neutralization of WT, B.1.1.7, and even E484K at high serum concentrations, but not B.1.351. The decreased potency and shallow Hill Slope prohibit >90% neutralization of B.1.351 even at the highest reciprocal serum dilution of 1 (see also Fig. 3E). Group (C) sera neutralize E484K and B.351 with potencies similar to WT

and B.1.1.7, especially at high serum concentrations. This group of sera reveals that qualitatively different neutralizing responses can be generated that can effectively neutralize B.1.351. The one serum in Group (D) appears unique. It exhibited little to no neutralizing activity against WT, E484K and B.1.351, yet it neutralized B.1.1.7 as well as Group A-C sera. This is obvious when comparing the reciprocal IC50s for B.1.1.7 (blue squares) across the four different groups of sera in Fig.3E.

The heterogenous dose-response curves described in Fig. 3 (and Fig. S2) is a property of Sputnik V vaccine elicited responses as soluble RBD-Fc inhibition of WT and VOC S-mediated entry produced classical dose response curves with Hill slopes close to -1.0 (Fig. 4A). RBD-Fc competition is an indirect measure of the virus spike affinity for human ACE2 expressed on the target F8-2 cell line. Both B.1.1.7 and B.1.351 were modestly but significantly more resistant to RBD-Fc inhibition (Fig. 4B). This is not surprising as both harbor the N501Y mutation known to enhance affinity of RBD for ACE2. However, this 1.5 to 2-fold increase in RBD-Fc IC<sub>50</sub> for B.1.1.7 and B.1.351, respectively, does not explain the neutralization-resistant versus sensitive phenotype of B.1.351 versus B.1.1.7 in our virus neutralization assays. Interestingly, each VOC or mutant clustered differently in the neutralization phenotype landscape defined by both IC50 and slope (Fig. 4C). These data suggest that the cognate VOC exhibit qualitatively distinct modes of escape from Sputnik vaccine neutralization (Webb, Montefiori and Lee, 2015).

### DISCUSSION

A key public health concern related to emergent SARS-CoV-2 variants is that by incrementally accruing mutations that escape neutralizing antibodies, they will penetrate herd immunity and spread to reach unvaccinated individuals, some of whom will be susceptible to severe or fatal disease.

Three of the six COVID-19 vaccines currently in use worldwide, namely Moderna mRNA-1273, BioNTech BNT162b2, and Janssen Ad26.COV2.S, each express S harboring K986P and V987P substitutions (2P) within a loop abutting the central helix of the S2' membrane fusion machinery (Bos *et al.*, 2020; Corbett *et al.*, 2020; Walsh *et al.*, 2020). This modification locks the spike in a prefusion conformation and elicits higher titers of neutralizing antibodies (Pallesen *et al.*, 2017; Wrapp *et al.*, 2020). Of the three vaccines that do not make use of 2P Spike mutants, Gamaleya's Sputnik V and AstraZeneca's AZD1222 are adenovirus-vectored vaccines encoding native S. The third is CoronaVac, a preparation of inactivated SARS-CoV-2 virions. Although all six vaccines are highly efficacious at preventing severe COVID-19 outcomes, they do not all uniformly prevent infection. Moreover, in all cases thus far examined, these first generation vaccines are less effective against variants with certain non-synonymous substitutions in Spike, such as E484K.

The most concerning variants are those with multiple mutations in the receptor binding domain (RBD) that confer both enhanced affinity for the hACE2 receptor and escape from neutralizing antibody responses (Tegally *et al.*, 2020; Cele *et al.*, 2021; Garcia-Beltran *et al.*, 2021; Hoffmann *et al.*, 2021; Madhi *et al.*, 2021; Zhou *et al.*, 2021). B.1.351 and P.1 have in common three RBD substitutions (K417N/T, E484K and N501Y) whereas all three WHO designated VOC contain the N501Y substitution. Although B.1.1.7 shows enhanced transmissibility and more severe disease outcomes(Davies, Abbott, *et al.*, 2021; Davies, Jarvis, *et al.*, 2021), it does not appear to be particularly more resistant to serum neutralizing responses elicited by vaccines or natural infection (Muik *et al.*, 2021; Shen *et al.*, 2021). The same is not true, however, for the B.1.351 variant.

In live virus plaque reduction neutralization assays, sera from AstraZeneca vaccine recipients in South Africa exhibited 4.1 to 32.5-fold reduction in neutralizing activity against B.1.351 (Madhi *et al.*, 2021). The actual reduction is even more marked because 7 of 12 vaccine recipients who had neutralizing activity against the parental B.1.1 variant, had undetectable neutralization against the B.1.351 strain. Comparator sera from recipients of Moderna and BioNTech mRNA vaccines showed smaller, 6.5 to 8.6-fold reductions in neutralization (Abdool Karim and de Oliveira, 2021).

As of this writing, there is no data on the protective efficacy of Sputnik V and CoronaVac against SARS-CoV-2 S variants. Here, we showed that sera from Sputnik vaccine recipients in Argentina had a median 6.1-fold and 2.8-fold reduction in neutralizing potency against B.1.351 and the E484K mutant spike, respectively. However, 8 of 12 sera samples (67%) exhibited dose-response curves against B.1.351 that suggested a failure to reach IC80 even in undiluted serum (Fig. S2A, B and D). One serum had little to no detectable neutralizing activity against B.1.351, E484K and even WT, but neutralized B.1.1.7 effectively. Altogether, these data suggest vaccines that do not use the 2P stabilized Spike appear to generate more variable neutralizing responses that make it difficult to establish immune correlates of protection, especially against emerging VOC/VOI that contain the recurrent E484K mutation.

E484K is present not only as part of an ensemble of RBD mutations present in B.1.351 and P.1, but in many of the 17 lineages detected from South America that carry it, such as P.2, E484K is the only RBD substitution (Supplementary Table 1). A more detailed report covering the genomic surveillance efforts in Argentina that detected the VOC which spurred our study is currently in preparation (Dr. Claudia Perandones, personal communication).

While the E484K substitution appears to be a common route of escape from many RBD-targeting monoclonal antibodies, it is somewhat surprising that a single mutation can confer a significant degree of neutralization resistance from polyclonal responses. Nonetheless, our data show that resistance conferred by E484K mutation be overcome by higher titer antibodies present in undiluted patient sera. But the neutralization resistance conferred by the suite of mutations present in B.1.351 appears qualitatively different. In the majority of cases, the slope of the dose response curve indicates a failure to neutralize even at full strength. We had previously shown that the dose-response curve slope is a major predictor of therapeutic potency for HIV broadly neutralizing antibodies at clinically relevant concentrations (Webb, Montefiori and Lee, 2015). Importantly, the slope parameter is independent of IC50 but is specifically related to an antibody's epitope class. Here, we show that defining the neutralization phenotype of a given spike variant or mutant by both its relative IC50 and slope provides a fuller characterization of serum neutralizing activity against SARS-CoV-2 spike and the emergent VOC.

Although we stress that the Gameyla Sputnik V vaccine is likely to retain strong efficacy at preventing severe COVID-19, even in the case of infection by VOC, our data reveal a concerning potential of B.1.351, and to a lesser extent, any variant carrying the E484K substitution (e.g. P.2), to escape the neutralizing antibody responses that this immunization elicits. Furthermore, we acknowledge that *in vivo* protective efficacy can be derived from Fc effector functions of antibodies that bind but do not neutralize. In

addition, an adenoviral vectored vaccine should induce potent cell-mediated immunity against multiple epitopes, which were not measured in our study. Nevertheless, given the crucial roles neutralizing antibodies play in preventing infection, our results suggest that updated SARS-CoV-2 vaccines will be necessary to eliminate the virus.

# **Materials and Methods**

# Cell lines

Vero-CCL81 TMPRSS2, HEK 293T-hACE2 (clone 5-7), and 293T-hACE2-TMPRSS2 (clone F8-2) cells were described previously (Oguntuyo *et al.*, 2021), and were maintained in DMEM + 10%FBS. The HEK 293T-hACE2-TMPRSS2 cells were plated on collagen coated plates or dishes. BSR-T7 cells (Buchholz, Finke and Conzelmann, 1999), which stably express T7-polymerase were maintained in DMEM with 10% FBS.

# VSV-eGFP-CoV2 spike ( $\Delta$ 21aa) genomic clone and helper plasmids.

We cloned VSV-eGFP sequence into pEMC vector (pEMC-VSV-eGFP), which includes an optimized T7 promoter and hammerhead ribozyme just before the 5' end of the viral genome. The original VSV-eGFP sequence was from pVSV-eGFP, a generous gift of Dr. John Rose (Ramsburg *et al.*, 2005).

We generated pEMC-VSV-eGFP-CoV2-S (Genbank Accession: MW816496) as follows: the VSV-G open reading frame of pEMC-VSV-eGFP was replaced with the SARS-CoV-2 S, truncated to lack the final 21 amino acids (Case, Rothlauf, Chen, Liu, *et al.*, 2020). We introduced a Pac-I restriction enzyme site just after the open reading frame of S transcriptional unit, such that the S transcriptional unit is flanked by Mlul / PacI sites. SARS-CoV-2 S is from pCAGGS-CoV-2-S (Amanat *et al.*, 2020), which codes the codon optimized S from the Wuhan Hu-1 isolate (NCBI ref. seq. NC\_045512.2) with a point mutation of D614G, resulting in B.1 lineage. The B.1.1.7 Spike we used carries the mutations found in GISAID Accession Number EPI\_ISL 668152: del 69-70, del145, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H. The B.1.351 Spike carries the mutations D80A, D215G, del242-244, K417N, E484K, N501Y, D614G, and A701V (from EPI\_ISL\_745109). The Spike sequences of WT, B.1.1.7, B.1.351, and E484K are available at Genbank (Accession Numbers: MW816497, MW816498, MW816499, and MW816500; please also see Supplemental Table 2).

Sequences encoding the VSV N, P, M, G, and L proteins were also cloned into pCI vector to make expression plasmids for virus rescue, resulting in plasmids: pCI-VSV-N, pCI-VSV-P, pCI-VSV-M, pCI-VSV-G, and pCI-VSV-L. These accessory plasmids were a kind gift from Dr. Benjamin tenOever.

#### Generation of VSV-CoV2 spike from cDNA

 $4 \times 10^5$  293T-ACE2-TMPRSS2 cells per well were seeded onto collagen-I coated 6 well plates. The next day, 2000 ng of pEMC-VSV-EGFP-CoV2 spike, 2500 ng of pCAGGS-T7opt (Beaty *et al.*, 2017), 850 ng of pCI-VSV-N, 400 ng of pCI-VSV-P, 100 ng of pCI-VSV-M, 100 ng of pCI-VSV-G, 100 ng of pCI-VSV-L were mixed with 4 mL of Plus reagent and 6.6 mL of Lipofectamine LTX (Invitrogen). 30 min later, transfection mixture was applied to 293T-hACE2-TMPRSS2 cells in a dropwise fashion. Cells were maintained with medium replacement every day for 4 to 5 days until GFP positive syncytia appeared. Rescued viruses were amplified in Vero-CCL81 TMPRSS2 cells (Oguntuyo *et al.*, 2021), then titered and used for the assay.

#### Virus neutralization assay

5 x 10E4 293T-hACE2-TMPRSS2 cells per well were seeded onto collagen-coated 96 well cluster plates one day prior to use in viral neutralization assays. Virus stocks were mixed with serially diluted serum for 10 minutes at room temperature, then infected to cells. Note: all sera assayed in this study were previously heat inactivated by 56 degrees for 30 min before use in any viral neutralization studies. At 10 h post infection, GFP counts were counted by Celigo imaging cytometer (Nexcelom). Each assay was done in triplicate. For calculation of IC50, GFP counts from "no serum" conditions were set to 100%; GFP counts of each condition (serum treated) were normalized to no serum control well. Inhibition curves were generated using Prism 8.4.3 (GraphPad Software) with 'log (inhibitor) vs normalized response - variable slope' settings.

#### Design of RBD-Fc producing Sendai virus

Sendai virus (SeV) Z strain cDNA sequence (AB855655.1) was generated and cloned into pRS vector with the addition of eGFP transcriptional unit at the head of SeV genome. The sequence of F transcriptional unit was from SeV fushimi strain (KY295909.1) due to the cloning reason. We refer to the pRS-based plasmid coding this sequence as pRS-SeVZ-GFP-F<sup>fushimi</sup> in this paper. For the introduction of foreign gene into SeV, we generated additional transcriptional unit for RBD-Fc between P gene and M gene. RBD-Fc construct was generated as below; codon optimized DNA sequence of from SARS-CoV-2 spike (MN908947) in pCAGGS a gift of Dr. Florian Krammer (Amanat *et al.*, 2020). S amino acids 319 – 541 (corresponding to the RBD domain) sequence were C-terminally fused to the Fc region of human IgG<sub>1</sub> (220 – 449 aa of P0DOX5.2)

# Generation of recombinant Sendai virus from cDNA.

2x10E5 BSR-T7 cells per well were seeded onto 6-well cluster plates. The next day, 4  $\mu$ g of pRS-SeVZ-GFP-F<sup>fushimi</sup>, 4  $\mu$ g of pCAGGS-T7opt, 1.44  $\mu$ g of SeV-N, 0.77 ug of SeV-P, 0.07 ug of SeV-L were mixed with 5.5  $\mu$ l of Plus reagent and 8.9  $\mu$ l of Lipofectamine LTX (Invitrogen). 30 min later, transfection mixtures were applied to Bsr-T7 cells in a dropwise fashion, as described previously (Beaty *et al.*, 2017). At one day post transfection, medium was replaced with DMEM + 0.2  $\mu$ g/ml of TPCK-trypsin (Millipore Sigma, #T1426), with subsequent medium replacement each day until infection reached 100% cytopathic effect. Supernatants were stored at -80°C until use in experiments.

# Titration of viruses.

For SeV titration, 2 x 10E4 Bsr-T7 cells per well were seeded onto 96-well plates. The next day, 100  $\mu$ L of serially diluted virus stock (in DMEM + 10% FBS) were applied to each well. GFP positive foci were counted at 24 hours post infection using a Celigo imaging cytometer (Nexcelom, Inc.). Infectivity is presented in infectious units (IU) per mL.

For VSV-CoV2 titration, 5 x 10E4 293T-hACE2-TMPRSS2 cells per well were seeded onto a collagen-coated 96 well plate. Serially diluted virus stocks were then applied to the cells, and GFP positivity was scored at 10 h post infection using a Celigo imaging cytometer.

# Production of proteins and purification.

 $5 \times 10E6$  Bsr-T7 cells are seeded in T175cm<sup>2</sup>-flask one day before infection. Cells were infected by SeV at MOI of 0.1 for one hour, followed by replacement of medium with DMEM supplemented with 0.2 mg/mL TPCK-trypsin. Medium was replaced with fresh 0.2 mg/ml TPCK-trypsin containing DMEM each day until infection reached 100% CPE, at which point medium was exchanged for DMEM lacking TPCK-trypsin. Cells were incubated for additional 24 h to allow protein production. Supernatants were centrifuged at 360 *g* for 5 min, then filtered with 0.1 µm filter (Corning<sup>®</sup> 500 mL Vacuum Filter/Storage Bottle System, 0.1 µm Pore) to remove virions and debris. Supernatant including RBD-Fc were applied to Protein G Sepharose (Millipore Sigma, #GE17-0618-01) containing column (5ml Polypropylene Columns ;ThermoFisher, #29922), followed by wash and elution.

### Human Subjects Research.

Human subjects research was conducted following the Declaration of Helsinki and related institutional and local regulations. Studies and serum collection relating to the Sputnik vaccine at ANLIS Dr. Carlos G. Malbrán (NatIonal Administration Laboratories and Health Institutes - Carlos G. Malbrán, Argentina) were approved by the Research Ethics Committee of its Unidad Operativa Centro de Contención Biológica (UOCCB) on 9 Feb 2021.

# **Authors contributions**

S.I., C.P., B.H.L., J.P.K, conceived of and supervised the study. S.I. generated VSV-CoV-2 S plasmid and rescued viruses. S.I., G.H., S.K., and M.N.A.S. were involved in the generation of S mutant viruses. M.N.A.S. and D.A.M. conducted neutralization assays. S.I., C.T.H., and P.A.T. developed Sendai virus protein expressing system and purified RBD-Fc protein. K.Y.O. tested RBD-Fc inhibition by using CoV2-VSVpp. S.I., B.H.L., and J.P.K. wrote the paper.

# Acknowledgements

We gratefully acknowledge all submitting authors and collecting authors on whose work this research is based, and to all researchers, clinicians, and public health authorities who make SARS-CoV-2 sequence data available in a timely manner via the GISAID initiative(Elbe and Buckland-Merrett, 2017; Shu and McCauley, 2017).

# **Funding information**

We acknowledge the following finding. K.Y.O. was supported by Viral-Host Pathogenesis Training Grant T32 Al07647 and additionally by a NRSA F31 Al154739. S.I. and C.-T.H. were supported by postdoctoral fellowships from CHOT-SG (Fukuoka University, Japan) and the Ministry of Science and Technology (MOST, Taiwan), respectively. B.L. acknowledges flexible funding support from NIH grants Al123449 and Al138921; a grant from the Department of Microbiology, Icahn School of Medicine at Mount Sinai; and the Ward-Coleman estate, which endowed the Ward-Coleman Chairs at the ISMMS. J.P.K. was supported by a COVID-19 Fast Grants award from Emergent Ventures, an initiative of the Mercatus Center at George Mason University, and by an intramural grant and other funding from the Office of the Vice Chancellor for Research at LSU Health Sciences Center Shreveport (J.P.K., M.N.A.S.). Processing costs recovered from multiple users of our standardized SARS-CoV-2 VSV pseudotyped particles provided additional support (BL). Work at ANLIS-MALBRAN (A.E.V., A.E., C.P.) was supported by the Ministry of Health (Ministerio de Salud), Argentina.

Table 1. Cohort characteristics of Sputnik vaccine recipients from ANLIS MALBRÁN(Buenos Aires, República Argentina).

Sera ID	1 <sup>st</sup> DOSE	2 <sup>nd</sup> DOSE	Vaccine Status	SEX	AGE
SP001	Late Dec/2020	Mid Jan/2021	(+)	М	45-50
SP002	Late Dec/2020	Mid Jan/2021	(+)	М	40-45
SP003	Late Dec/2020	Mid Jan/2021	(+)	М	55-60
SP004	Late Dec/2020	Mid Jan/2021	(+)	М	50-55
SP005	Late Dec/2020	Mid Jan/2021	(+)	М	35-40
SP006	Late Dec/2020	Mid Jan/2021	(+)	F	35-40
SP007	Late Dec/2020	Mid Jan/2021	(+)	F	20-25
SP008	Late Dec/2020	Early Feb/2021	(+)	М	35-40
SP009	Late Dec/2020	Early Feb/2021	(+)	F	30-35
SP010	Late Dec/2020	Mid Jan/2021	(+)	М	30-35
SP011	Late Dec/2020	Mid Jan/2021	(+)	М	40-45
SP012	Late Dec/2020	Mid Jan/2021	(+)	М	25-30
				Median Age	39.5
				Range	25-56
SP013	N.A.	N.A.	(-)	F	45-50
SP014	N.A.	N.A.	(-)	F	50-55
SP015	N.A.	N.A.	(-)	М	40-45

N.A., Not Applicable

SUPPLEMENTAL TABLE 1. Acknowledgement of S: E484K viruses from South America shared on GISAID.

**SUPPLEMENTAL TABLE 2.** Acknowledgement of B.1.1.7 and B.1.351 viruses used for selection of S variants evaluated in this study.

#### REFERENCES

Abdool Karim, S. S. and de Oliveira, T. (2021) 'New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications', *The New England Journal of Medicine*. Massachusetts Medical Society. doi: 10.1056/NEJMc2100362.

Addetia, A., Crawford, K. H. D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.-L., Jerome, K. R., Bloom, J. D. and Greninger, A. L. (2020) 'Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate', *Journal of Clinical Microbiology*. Am Soc Microbiol, 58(11). doi: 10.1128/JCM.02107-20.

Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V.,
McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J.,
Bermudez-Gonzalez, M., Kleiner, G., Aydillo, T., Miorin, L., Fierer, D. S., Lugo, L. A.,
Kojic, E. M., Stoever, J., Liu, S. T. H., Cunningham-Rundles, C., Felgner, P. L., Moran,
T., García-Sastre, A., Caplivski, D., Cheng, A. C., Kedzierska, K., Vapalahti, O.,
Hepojoki, J. M., Simon, V. and Krammer, F. (2020) 'A serological assay to detect
SARS-CoV-2 seroconversion in humans', *Nature Medicine*. nature.com. doi:
10.1038/s41591-020-0913-5.

Andrew Rambaut, Nick Loman, Oliver Pybus, Wendy Barclay, Jeff Barrett, Alesandro Carabelli, Tom Connor, Tom Peacock, David L Robertson, Erik Volz, COVID-19 Genomics Consortium UK (CoG-UK) (2020) *Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations, Virological.org.* Available at:

https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov -2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563 (Accessed: 12 February 2021).

Annavajhala, M. K., Mohri, H., Zucker, J. E., Sheng, Z., Wang, P., Gomez-Simmonds, A., Ho, D. D. and Uhlemann, A.-C. (2021) 'A novel SARS-CoV-2 variant of concern, B.1.526, identified in New York', *bioRxiv*. medRxiv. doi: 10.1101/2021.02.23.21252259.

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., Zaks, T. and COVE Study Group (2021) 'Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine', *The New England Journal of Medicine*. Massachusetts Medical Society, 384(5), pp. 403–416. doi: 10.1056/NEJMoa2035389. Baum, A., Fulton, B. O., Wloga, E., Copin, R., Pascal, K. E., Russo, V., Giordano, S., Lanza, K., Negron, N., Ni, M., Wei, Y., Atwal, G. S., Murphy, A. J., Stahl, N., Yancopoulos, G. D. and Kyratsous, C. A. (2020) 'Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies', *Science*, 369(6506), pp. 1014–1018. doi: 10.1126/science.abd0831.

Beaty, S. M., Park, A., Won, S. T., Hong, P., Lyons, M., Vigant, F., Freiberg, A. N., tenOever, B. R., Duprex, W. P. and Lee, B. (2017) 'Efficient and Robust Paramyxoviridae Reverse Genetics Systems', *mSphere*, 2(2). doi: 10.1128/mSphere.00376-16.

Boni, M. F., Lemey, P., Jiang, X., Lam, T. T.-Y., Perry, B. W., Castoe, T. A., Rambaut, A. and Robertson, D. L. (2020) 'Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic', *Nature Microbiology*, 382, p. 1199. doi: 10.1038/s41564-020-0771-4.

Bos, R., Rutten, L., van der Lubbe, J. E. M., Bakkers, M. J. G., Hardenberg, G., Wegmann, F., Zuijdgeest, D., de Wilde, A. H., Koornneef, A., Verwilligen, A., van Manen, D., Kwaks, T., Vogels, R., Dalebout, T. J., Myeni, S. K., Kikkert, M., Snijder, E. J., Li, Z., Barouch, D. H., Vellinga, J., Langedijk, J. P. M., Zahn, R. C., Custers, J. and Schuitemaker, H. (2020) 'Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses', *NPJ vaccines*. nature.com, 5, p. 91. doi: 10.1038/s41541-020-00243-x.

Buchholz, U. J., Finke, S. and Conzelmann, K. K. (1999) '... respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional ...', *Journal of Virology*. Am Soc Microbiol. Available at: https://jvi.asm.org/content/73/1/251.short.

Case, J. B., Rothlauf, P. W., Chen, R. E., Kafai, N. M., Fox, J. M., Smith, B. K., Shrihari, S., McCune, B. T., Harvey, I. B., Keeler, S. P., Bloyet, L.-M., Zhao, H., Ma, M., Adams, L. J., Winkler, E. S., Holtzman, M. J., Fremont, D. H., Whelan, S. P. J. and Diamond, M. S. (2020) 'Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice', *Cell Host & Microbe*, 28(3), pp. 465–474.e4. doi: 10.1016/j.chom.2020.07.018.

Case, J. B., Rothlauf, P. W., Chen, R. E., Liu, Z., Zhao, H., Kim, A. S., Bloyet, L.-M., Zeng, Q., Tahan, S., Droit, L., Ilagan, M. X. G., Tartell, M. A., Amarasinghe, G., Henderson, J. P., Miersch, S., Ustav, M., Sidhu, S., Virgin, H. W., Wang, D., Ding, S., Corti, D., Theel, E. S., Fremont, D. H., Diamond, M. S. and Whelan, S. P. J. (2020) 'Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2', *Cell Host & Microbe*, 28(3), pp. 475–485.e5. doi: 10.1016/j.chom.2020.06.021. Cele, S., Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., Wilkinson, E., Naidoo, Y. and Others (2021) 'Escape of SARS-CoV-2 501Y. V2 from neutralization by convalescent plasma', *medRxiv*. Cold Spring Harbor Laboratory Press. Available at:

https://www.medrxiv.org/content/10.1101/2021.01.26.21250224v2.abstract.

Choi, B., Choudhary, M. C., Regan, J., Sparks, J. A., Padera, R. F., Qiu, X., Solomon, I. H., Kuo, H.-H., Boucau, J., Bowman, K., Adhikari, U. D., Winkler, M. L., Mueller, A. A., Hsu, T. Y.-T., Desjardins, M., Baden, L. R., Chan, B. T., Walker, B. D., Lichterfeld, M., Brigl, M., Kwon, D. S., Kanjilal, S., Richardson, E. T., Jonsson, A. H., Alter, G., Barczak, A. K., Hanage, W. P., Yu, X. G., Gaiha, G. D., Seaman, M. S., Cernadas, M. and Li, J. Z. (2020) 'Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host', *The New England Journal of Medicine*, 383(23), pp. 2291–2293. doi: 10.1056/NEJMc2031364.

Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., Dinnon, K. H., Elbashir, S. M., Shaw, C. A., Woods, A., Fritch, E. J., Martinez, D. R., Bock, K. W., Minai, M., Nagata, B. M., Hutchinson, G. B., Wu, K., Henry, C., Bahl, K., Garcia-Dominguez, D., Ma, L., Renzi, I., Kong, W.-P., Schmidt, S. D., Wang, L., Zhang, Y., Phung, E., Chang, L. A., Loomis, R. J., Altaras, N. E., Narayanan, E., Metkar, M., Presnyak, V., Liu, C., Louder, M. K., Shi, W., Leung, K., Yang, E. S., West, A., Gully, K. L., Stevens, L. J., Wang, N., Wrapp, D., Doria-Rose, N. A., Stewart-Jones, G., Bennett, H., Alvarado, G. S., Nason, M. C., Ruckwardt, T. J., McLellan, J. S., Denison, M. R., Chappell, J. D., Moore, I. N., Morabito, K. M., Mascola, J. R., Baric, R. S., Carfi, A. and Graham, B. S. (2020) 'SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness', *Nature*. Springer Science and Business Media LLC, 586(7830), pp. 567–571. doi: 10.1038/s41586-020-2622-0.

*COVID-19 Map - Johns Hopkins Coronavirus Resource Center* (no date). Available at: https://coronavirus.jhu.edu/map.html (Accessed: 14 March 2021).

Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., Wenseleers, T., Gimma, A., Waites, W., Wong, K. L. M., van Zandvoort, K., Silverman, J. D., CMMID COVID-19 Working Group, COVID-19 Genomics UK (COG-UK) Consortium, Diaz-Ordaz, K., Keogh, R., Eggo, R. M., Funk, S., Jit, M., Atkins, K. E. and Edmunds, W. J. (2021) 'Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England', *Science*. doi: 10.1126/science.abg3055.

Davies, N. G., Jarvis, C. I., CMMID COVID-19 Working Group, Edmunds, W. J., Jewell, N. P., Diaz-Ordaz, K. and Keogh, R. H. (2021) 'Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7', *Nature*. doi: 10.1038/s41586-021-03426-1.

Dejnirattisai, W., Zhou, D., Supasa, P., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Tuekprakhon, A., Nutalai, R., Wang, B., Paesen, G. C., López-Camacho, C., Slon-Campos, J., Walter, T. S., Skelly, D., Clemens, S. A. C., Naveca, F. G., Nascimento, V., Nascimento, F., da Costa, C. F., Dold, C., Levin, R., Dong, T., Pollard, A. J., Knight, J. C., Crook, D., Lambe, T., Clutterbuck, E., Bibi, S., Flaxman, A., Bittaye, M., Belij-Rammerstorfer, S., Gilbert, S., Carroll, M. W., Klenerman, P., Barnes, E., Dunachie, S. J., Paterson, N. G., Williams, M. A., Hall, D. R., Hulswit, R. J. G., Bowden, T. A., Fry, E. E., Mongkolsapaya, J., Ren, J., Stuart, D. I. and Screaton, G. R. (2021) 'Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2', BioRxiv. *Cold Spring Harbor Laboratory*. doi: 10.1101/2021.03.12.435194.

Dieterle, M. E., Haslwanter, D., Bortz, R. H. 3rd, Wirchnianski, A. S., Lasso, G., Vergnolle, O., Abbasi, S. A., Fels, J. M., Laudermilch, E., Florez, C., Mengotto, A., Kimmel, D., Malonis, R. J., Georgiev, G., Quiroz, J., Barnhill, J., Pirofski, L.-A., Daily, J. P., Dye, J. M., Lai, J. R., Herbert, A. S., Chandran, K. and Jangra, R. K. (2020) 'A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition', *Cell Host & Microbe*, 28(3), pp. 486–496.e6. doi: 10.1016/j.chom.2020.06.020.

Elbe, S. and Buckland-Merrett, G. (2017) 'Data, disease and diplomacy: GISAID's innovative contribution to global health', *Global challenges (Hoboken, NJ)*. Wiley Online Library, 1(1), pp. 33–46. doi: 10.1002/gch2.1018.

Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., Dold, C., Faust, S. N., Finn, A., Flaxman, A. L., Hallis, B., Heath, P., Jenkin, D., Lazarus, R., Makinson, R., Minassian, A. M., Pollock, K. M., Ramasamy, M., Robinson, H., Snape, M., Tarrant, R., Voysey, M., Green, C., Douglas, A. D., Hill, A. V. S., Lambe, T., Gilbert, S. C., Pollard, A. J. and Oxford COVID Vaccine Trial Group (2020) 'Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial', *The Lancet*, 396(10249), pp. 467–478. doi: 10.1016/S0140-6736(20)31604-4.

Garcia-Beltran, W. F., Lam, E. C., St Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., Sigal, A., Schmidt, A. G., lafrate, A. J., Naranbhai, V. and Balazs, A. B. (2021) 'Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity', *Cell*. doi: 10.1016/j.cell.2021.03.013.

Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y. and Bloom, J. D. (2021) 'Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies', *Cell Host & Microbe*, 29(3), pp. 463–476.e6. doi:

10.1016/j.chom.2021.02.003.

Greaney, A. J., Starr, T. N., Gilchuk, P., Zost, S. J., Binshtein, E., Loes, A. N., Hilton, S. K., Huddleston, J., Eguia, R., Crawford, K. H. D., Dingens, A. S., Nargi, R. S., Sutton, R. E., Suryadevara, N., Rothlauf, P. W., Liu, Z., Whelan, S. P. J., Carnahan, R. H., Crowe, J. E., Jr and Bloom, J. D. (2021) 'Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition', *Cell Host & Microbe*, 29(1), pp. 44–57.e9. doi: 10.1016/j.chom.2020.11.007.

Grint, D. J., Wing, K., Williamson, E., McDonald, H. I., Bhaskaran, K., Evans, D., Evans, S. J. W., Walker, A. J., Hickman, G., Nightingale, E., Schultze, A., Rentsch, C. T., Bates, C., Cockburn, J., Curtis, H. J., Morton, C. E., Bacon, S., Davy, S., Wong, A. Y. S., Mehrkar, A., Tomlinson, L., Douglas, I. J., Mathur, R., Blomquist, P., MacKenna, B., Ingelsby, P., Croker, R., Parry, J., Hester, F., Harper, S., DeVito, N. J., Hulme, W., Tazare, J., Goldacre, B., Smeeth, L. and Eggo, R. M. (2021) 'Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England', *bioRxiv*. medRxiv. doi: 10.1101/2021.03.04.21252528.

Hoffmann, M., Arora, P., Groß, R., Seidel, A., Hörnich, B. F., Hahn, A. S., Krüger, N., Graichen, L., Hofmann-Winkler, H., Kempf, A., Winkler, M. S., Schulz, S., Jäck, H.-M., Jahrsdörfer, B., Schrezenmeier, H., Müller, M., Kleger, A., Münch, J. and Pöhlmann, S. (2021) 'SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies', *Cell*. Elsevier. doi: 10.1016/j.cell.2021.03.036.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., Gao, H., Guo, L., Xie, J., Wang, G., Jiang, R., Gao, Z., Jin, Q., Wang, J. and Cao, B. (2020) 'Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China', *The Lancet*, 395(10223), pp. 497–506. doi: 10.1016/S0140-6736(20)30183-5.

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A. and Davenport, M. P. (2021) 'What level of neutralising antibody protects from COVID-19?', *bioRxiv*. medRxiv. doi: 10.1101/2021.03.09.21252641.

Li, H., Zhao, C., Zhang, Y., Yuan, F., Zhang, Q., Shi, X., Zhang, L., Qin, C. and Zheng, A. (2020) 'Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays', *Emerging microbes & infections*, 9(1), pp. 2269–2277. doi: 10.1080/22221751.2020.1830715.

Liu, Y., Liu, J., Xia, H., Zhang, X., Fontes-Garfias, C. R., Swanson, K. A., Cai, H., Sarkar, R., Chen, W., Cutler, M., Cooper, D., Weaver, S. C., Muik, A., Sahin, U., Jansen, K. U., Xie, X., Dormitzer, P. R. and Shi, P.-Y. (2021) 'Neutralizing Activity of BNT162b2-Elicited

Serum', The New England journal of medicine. doi: 10.1056/NEJMc2102017.

Liu, Z., VanBlargan, L. A., Bloyet, L.-M., Rothlauf, P. W., Chen, R. E., Stumpf, S., Zhao, H., Errico, J. M., Theel, E. S., Liebeskind, M. J., Alford, B., Buchser, W. J., Ellebedy, A. H., Fremont, D. H., Diamond, M. S. and Whelan, S. P. J. (2021) 'Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization', *Cell Host & Microbe*. Elsevier, 0(0). doi: 10.1016/j.chom.2021.01.014.

Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., Kovyrshina, A. V., Lubenets, N. L., Grousova, D. M., Erokhova, A. S., Botikov, A. G., Izhaeva, F. M., Popova, O., Ozharovskaya, T. A., Esmagambetov, I. B., Favorskaya, I. A., Zrelkin, D. I., Voronina, D. V., Shcherbinin, D. N., Semikhin, A. S., Simakova, Y. V., Tokarskaya, E. A., Egorova, D. A., Shmarov, M. M., Nikitenko, N. A., Gushchin, V. A., Smolyarchuk, E. A., Zyryanov, S. K., Borisevich, S. V., Naroditsky, B. S., Gintsburg, A. L. and Gam-COVID-Vac Vaccine Trial Group (2021) 'Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia', *The Lancet*, 397(10275), pp. 671–681. doi: 10.1016/S0140-6736(21)00234-8.

Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., Grousova, D. M., Erokhova, A. S., Kovyrshina, A. V., Botikov, A. G., Izhaeva, F. M., Popova, O., Ozharovskaya, T. A., Esmagambetov, I. B., Favorskaya, I. A., Zrelkin, D. I., Voronina, D. V., Shcherbinin, D. N., Semikhin, A. S., Simakova, Y. V., Tokarskaya, E. A., Lubenets, N. L., Egorova, D. A., Shmarov, M. M., Nikitenko, N. A., Morozova, L. F., Smolyarchuk, E. A., Kryukov, E. V., Babira, V. F., Borisevich, S. V., Naroditsky, B. S. and Gintsburg, A. L. (2020) 'Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia', *The Lancet*. Elsevier, 396(10255), pp. 887–897. doi: 10.1016/S0140-6736(20)31866-3.

Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., Briner, C., Kwatra, G., Ahmed, K., Aley, P., Bhikha, S., Bhiman, J. N., Bhorat, A. E., du Plessis, J., Esmail, A., Groenewald, M., Horne, E., Hwa, S.-H., Jose, A., Lambe, T., Laubscher, M., Malahleha, M., Masenya, M., Masilela, M., McKenzie, S., Molapo, K., Moultrie, A., Oelofse, S., Patel, F., Pillay, S., Rhead, S., Rodel, H., Rossouw, L., Taoushanis, C., Tegally, H., Thombrayil, A., van Eck, S., Wibmer, C. K., Durham, N. M., Kelly, E. J., Villafana, T. L., Gilbert, S., Pollard, A. J., de Oliveira, T., Moore, P. L., Sigal, A., Izu, A. and NGS-SA Group Wits–VIDA COVID Group (2021) 'Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant', *The New England Journal of Medicine*. doi: 10.1056/NEJMoa2102214.

Muik, A., Wallisch, A.-K., Sänger, B., Swanson, K. A., Mühl, J., Chen, W., Cai, H., Maurus, D., Sarkar, R., Türeci, Ö., Dormitzer, P. R. and Şahin, U. (2021) 'Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera', *Science*, 371(6534), pp. 1152–1153. doi: 10.1126/science.abg6105.

Naveca, F., da Costa, C., Nascimento, V., Souza, V., Corado, A., Nascimento, F., Costa, Á., Duarte, D., Silva, G., Mejía, M. and Others (2021) 'SARS-CoV-2 reinfection by the new Variant of Concern (VOC) P. 1 in Amazonas, Brazil', *virological. org. Preprint available at: https://virological.* 

org/t/sars-cov-2-reinfection-by-thenew-variant-of-concern-voc-p-1-in-a mazonas-brazil/596. virological.org. Available at:

https://virological.org/t/sars-cov-2-reinfection-by-the-new-variant-of-concern-voc-p-1-in-amazonas-brazil/596.

Oguntuyo, K. Y., Stevens, C. S., Hung, C. T., Ikegame, S., Acklin, J. A., Kowdle, S. S., Carmichael, J. C., Chiu, H.-P., Azarm, K. D., Haas, G. D. and Others (2021) 'Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera', *mBio*. Am Soc Microbiol, 12(1). Available at:

https://mbio.asm.org/content/12/1/e02492-20.abstract.

Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., Kong, W.-P., Andres, E. L., Kettenbach, A. N., Denison, M. R., Chappell, J. D., Graham, B. S., Ward, A. B. and McLellan, J. S. (2017) 'Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen', *Proceedings of the National Academy of Sciences of the United States of America*, 114(35), pp. E7348–E7357. doi: 10.1073/pnas.1707304114.

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Jr, Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., Gruber, W. C. and C4591001 Clinical Trial Group (2020) 'Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine', *The New England Journal of Medicine*. Mass Medical Soc, 383(27), pp. 2603–2615. doi: 10.1056/NEJMoa2034577.

Ramsburg, E., Publicover, J., Buonocore, L., Poholek, A., Robek, M., Palin, A. and Rose, J. K. (2005) 'A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals', *Journal of virology*. Am Soc Microbiol, 79(24), pp. 15043–15053. Available at: https://jvi.asm.org/content/79/24/15043.short.

Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A. M., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., Berghmans, P.-J., Kimmel, M.,

Van Damme, P., de Hoon, J., Smith, W., Stephenson, K. E., De Rosa, S. C., Cohen, K. W., McElrath, M. J., Cormier, E., Scheper, G., Barouch, D. H., Hendriks, J., Struyf, F., Douoguih, M., Van Hoof, J. and Schuitemaker, H. (2021) 'Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine', *The New England Journal of Medicine*. Massachusetts Medical Society. doi: 10.1056/NEJMoa2034201.

Shen, X., Tang, H., McDanal, C., Wagh, K., Fischer, W., Theiler, J., Yoon, H., Li, D., Haynes, B. F., Sanders, K. O., Gnanakaran, S., Hengartner, N., Pajon, R., Smith, G., Glenn, G. M., Korber, B. and Montefiori, D. C. (2021) 'SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines', *Cell Host & Microbe*. Elsevier. doi: 10.1016/j.chom.2021.03.002.

Shu, Y. and McCauley, J. (2017) 'GISAID: Global initiative on sharing all influenza data - from vision to reality', *Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin*. ncbi.nlm.nih.gov, 22(13). doi: 10.2807/1560-7917.ES.2017.22.13.30494.

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., Mlisana, K., von Gottberg, A., Walaza, S., Allam, M., Ismail, A., Mohale, T., Glass, A. J., Engelbrecht, S., Van Zyl, G., Preiser, W., Petruccione, F., Sigal, A., Hardie, D., Marais, G., Hsiao, M., Korsman, S., Davies, M.-A., Tyers, L., Mudau, I., York, D., Maslo, C., Goedhals, D., Abrahams, S., Laguda-Akingba, O., Alisoltani-Dehkordi, A., Godzik, A., Wibmer, C. K., Sewell, B. T., Lourenço, J., Alcantara, L. C. J., Pond, S. L. K., Weaver, S., Martin, D., Lessells, R. J., Bhiman, J. N., Williamson, C. and de Oliveira, T. (2020) 'Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa', *bioRxiv*. medRxiv. doi: 10.1101/2020.12.21.20248640.

Voloch, C. M., da Silva Francisco, R., Jr, de Almeida, L. G. P., Cardoso, C. C., Brustolini, O. J., Gerber, A. L., Guimarães, A. P. de C., Mariani, D., da Costa, R. M., Ferreira, O. C., Jr, Covid19-UFRJ Workgroup, LNCC Workgroup, Adriana Cony Cavalcanti, Frauches, T. S., de Mello, C. M. B., Leitão, I. de C., Galliez, R. M., Faffe, D. S., Castiñeiras, T. M. P. P., Tanuri, A. and de Vasconcelos, A. T. R. (2021) 'Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil', *Journal of Virology*. doi: 10.1128/JVI.00119-21.

Walsh, E. E., Frenck, R. W., Jr, Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A.,
Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., Swanson, K. A., Li, P., Koury, K.,
Kalina, W., Cooper, D., Fontes-Garfias, C., Shi, P.-Y., Türeci, Ö., Tompkins, K. R., Lyke,
K. E., Raabe, V., Dormitzer, P. R., Jansen, K. U., Şahin, U. and Gruber, W. C. (2020)
'Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates', *The New England journal of medicine*, 383(25), pp. 2439–2450. doi:
10.1056/NEJMoa2027906.

Wang, P., Wang, M., Yu, J., Cerutti, G., Nair, M. S. and Huang, Y. (2021) 'Increased Resistance of SARS-CoV-2 Variant P. 1 to Antibody Neutralization', *BioRxiv*. ncbi.nlm.nih.gov. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941628/.

Webb, N. E., Montefiori, D. C. and Lee, B. (2015) 'Dose–response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies', *Nature communications*. Nature Publishing Group, 6(1), pp. 1–10. doi: 10.1038/ncomms9443.

Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., Gaebler, C., Agudelo, M., Cho, A., Wang, Z., Gazumyan, A., Cipolla, M., Luchsinger, L., Hillyer, C. D., Caskey, M., Robbiani, D. F., Rice, C. M., Nussenzweig, M. C., Hatziioannou, T. and Bieniasz, P. D. (2020) 'Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants', *eLife*, 9. doi: 10.7554/eLife.61312.

West, A. P., Barnes, C. O., Yang, Z. and Bjorkman, P. J. (2021) 'SARS-CoV-2 lineage B.1.526 emerging in the New York region detected by software utility created to query the spike mutational landscape', BioRxiv. *Cold Spring Harbor Laboratory*. doi: 10.1101/2021.02.14.431043.

Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., Rossouw, T., Boswell, M., Ueckermann, V., Meiring, S., von Gottberg, A., Cohen, C., Morris, L., Bhiman, J. N. and Moore, P. L. (2021) 'SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma', *Nature Medicine*. nature.com. doi: 10.1038/s41591-021-01285-x.

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S. and McLellan, J. S. (2020) 'Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation', *Science*, 367(6483), pp. 1260–1263. doi: 10.1126/science.abb2507.

Yahalom-Ronen, Y., Tamir, H., Melamed, S., Politi, B., Shifman, O., Achdout, H., Vitner, E. B., Israeli, O., Milrot, E., Stein, D., Cohen-Gihon, I., Lazar, S., Gutman, H., Glinert, I., Cherry, L., Vagima, Y., Lazar, S., Weiss, S., Ben-Shmuel, A., Avraham, R., Puni, R., Lupu, E., Bar-David, E., Sittner, A., Erez, N., Zichel, R., Mamroud, E., Mazor, O., Levy, H., Laskar, O., Yitzhaki, S., Shapira, S. C., Zvi, A., Beth-Din, A., Paran, N. and Israely, T. (2020) 'A single dose of recombinant VSV- $\Delta$ G-spike vaccine provides protection against SARS-CoV-2 challenge', *Nature Communications*, 11(1), p. 6402. doi: 10.1038/s41467-020-20228-7.

Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W. and Others (2020) 'Safety, tolerability, and immunogenicity of an inactivated

SARS-CoV-2 vaccine in healthy adults aged 18--59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial', *The Lancet Infectious Diseases*. Elsevier. Available at: https://www.sciencedirect.com/science/article/pii/S1473309920308434.

Zhou, D., Dejnirattisai, W., Supasa, P., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y.,
Duyvesteyn, H. M. E., Tuekprakhon, A., Nutalai, R., Wang, B., Paesen, G. C.,
Lopez-Camacho, C., Slon-Campos, J., Hallis, B., Coombes, N., Bewley, K., Charlton,
S., Walter, T. S., Skelly, D., Lumley, S. F., Dold, C., Levin, R., Dong, T., Pollard, A. J.,
Knight, J. C., Crook, D., Lambe, T., Clutterbuck, E., Bibi, S., Flaxman, A., Bittaye, M.,
Belij-Rammerstorfer, S., Gilbert, S., James, W., Carroll, M. W., Klenerman, P., Barnes,
E., Dunachie, S. J., Fry, E. E., Mongkolsapaya, J., Ren, J., Stuart, D. I. and Screaton, G.
R. (2021) 'Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and
vaccine-induced sera', *Cell*. Elsevier. doi: 10.1016/j.cell.2021.02.037.



#### Figure 1. Generation of replication-competent VSV bearing SARS-CoV-2 spike

(rcVSV-CoV2-S). (A) Schematic of the rcVSV-CoV2-S genomic coding construct and the virus rescue procedure. The maximal T7 promoter (T7prom) followed by a hammer-head ribozyme (HhRbz) and the HDV ribozyme (HDVRbz) plus T7 terminator (T7term) are positioned at the 3' and 5' ends of the viral cDNA, respectively. An EGFP(E) transcriptional unit is placed at the 3' terminus to allow for high level transcription. SARS-CoV-2-S is cloned in place of VSV-G using the indicated restriction sites designed to facilitate easy exchange of spike variants or mutants. For virus rescue, highly permissive 293T-ACE2+TMPRSS2 (F8-2 clones) cells were transfected with the genome coding plasmid, helper plasmids encoding CMV-driven N, P, M, and L genes, and pCAGS encoding codon-optimized T7-RNA polymerase(T7opt-RNAP). 48-72 hpi, transfected cells turn EGFP+ and start forming syncytia. Supernatants containing rcVSV-CoV2-S are then amplified in Vero-TMPRSS2 cells. (B) Representative images of de novo generation of rcVSV-CoV2-S in transfected 293T-ACE2-TMPRSS2 (F8-2) cells as described in (A). Single GFP+ cells are detectable at 2-3 days post-transfection (dpt). Some of these form a foci of syncytia by 4 dpt. Images are taken by Celigo imaging cytometer (Nexcelom) and are computational composites from the identical number of fields in each well. White bar is equal to 1 millimeter. (C) Left panel: Entry efficiency of rcVSV-CoV2-S in parental 293T cells, 293T stably expressing ACE2 alone (293T-ACE2) or with TMPRSS2 (293T-ACE2+TMPRSS2). Serial dilutions of virus stocks amplified on Vero-TMPRSS2 cells were used to infect the indicated cell lines in 96-well plates in triplicates. GFP signal was detected and counted by a Celigo imaging cytometer (Nexcelom) 10 hpi, Symbols represent the average of 3 replicates with error bars indicating standard deviation. Right Panel: Data from the gray shaded box in the left panel is expanded to show the individual data points at the indicated dilutions. 2 way-ANOVA was used to compare the differences between cell lines at any given dilution. Adjusted p values from Tukey's multiple comparisons test are given (ns; not significant, \* p < 0.05, \*\* p < 0.01, \*\*\* p = 0.001, \*\*\*\* p < 0.001).



Figure 2. Neutralization activity of antibody responses elicited by the Sputnik V vaccine. (A) Schematic of the Spike substitutions that make up the variants being evaluated in this study. The amino acid positions and corresponding 'Ancestral' sequence of the Wuhan isolate used as the template for the Sputnik vaccine is shown. This has now been replaced by the 'prevailing WT' sequence which has a D614G substitution. All the variants and mutants have D614G. (B) Neutralization activity of individual serum samples against rcVSV-CoV2-S with the wild-type (614G, WT), variant (B.1.1.7 or B.1.351), or mutant E484K spike proteins. Neutralization is represented by the reciprocal 50% inhibitory dilution factor  $(1/IC_{50})$ . Sera samples with no significant neutralization against a given virus, or that could not achieve a best fit by non-linear regression, were assigned a defined  $1/IC_{50}$  value of 1.0. Values below 1.0 are not physiologically relevant (gray shaded box). Geometric mean titers (GMT and 95% CI) for the neutralizing activity of all vaccine sera are indicated below each of the viral spike proteins examined. NS; not significant, \*; p<0.05, p < 0.01; \*\* are adjusted p values from non-parametric one-way ANOVA with Dunn's multiple comparisons test. (C) For each serum sample, the fold-change in IC<sub>50</sub> (reciprocal inhibitory dilution factor) against the indicated variant and mutant spike proteins relative to its IC<sub>50</sub> against wild-type (WT) spike (set at 1) is plotted. Adjusted p values were calculated as in (B). Medians are represented by the bars and whiskers demarcate the 95% CI. Neutralization dose-response curves were performed in triplicates, and the mean values from each triplicate experiment are shown as the single data points for each sera sample.



**Figure 3.** Dose response curves reveal distinct patterns of neutralizing antibody responses. Groups (A - D) represent distinct classes of virus neutralizing activity present in the sera samples analyzed. A representative member from each group is shown. Full neutralization curves for all sera tested against all viruses bearing the variant and mutant spike proteins are shown in supplementary Fig. S2. (E) graphs the virus neutralizing titers (VNT =  $1/IC_{50}$ ) and 95% CI that can be extrapolated from the nonlinear regression curves. Different colored symbols represent the viruses indicated in the figure key. The open symbols in SP012 (Group D) represent assigned values of 1.0 (for B.1.351 and E484K) when no significant neutralization activity could be detected at the lowest serum dilution used (1:20) or ambiguous fits (for WT) due to very low neutralizing activity. The shaded area represents values that are not physiologically relevant.





p<0.0001) from ordinary one-way ANOVA with Dunnett's multiple comparisons test are indicated. **(C)** Landscape of slope versus relative IC50 values of all 12 Sputnik sera against the indicated VOC or mutant Spike. Relative IC50 value is defined as the ratio of fold-change WT:VOC IC50 where WT IC50 is defined as 1.0. Dashed lines indicate quadrants of high/low IC50 and high/low slope.



Figure S1. Spike variants with the E484K mutation shows marked resistance to neutralization. Since some B.1.351 and E484K neutralization curves cannot be accurately extrapolated, and some do not reach IC50 even at the highest serum concentration used (1:20), we compared the *maximal percent inhibited (MPI)* at this concentration across all sera samples. The majority of sera inhibited viruses bearing WT and B.1.1.7 spikes (median MPI = 76.8% and 82.4%, respectively) significantly better than those bearing B.1.351 or E484K alone (median MPI = 42.7% and 49.3%, respectively). Data points (color circles) represent the means for each sera sample (n=12) performed in triplicates. Median and interquartile range are indicated. Adjusted P values: \*, P<0.05; \*\*p<0.005 (non-parametric Friedman test with Dunn's multiple comparisons).



**Figure S2.** Sputnik vaccine elicits qualitatively different polyclonal responses against SARS-CoV-2 Spike. The full neutralization dose-response curves for all four classes of sera described in Fig. 3 are shown. Data points are mean of 3 independent replicates with error bars representing S.D. Infection (GFP+ cells) at each serum dilution was normalized to that obtained in the absence of any serum (set at 100%). Nonlinear regression of log [reciprocal serum dilution] versus normalized infection was performed using GraphPad PRISM (v9.0.1). Dotted lines represent 50% of maximal infection.